Bal Pharma Limited: Statement of Deviation/Variation Not Applicable for Q4FY26
Bal Pharma Limited states that the statement of deviation/variation in fund utilization is not applicable for the quarter ended March 31, 2026. The company has not raised funds via public issue, rights issue, preferential issue, or QIP, and has no outstanding funds from earlier issues requiring utilization.
This is a routine regulatory clarification and does not involve any new financial events, operational changes, or strategic decisions that would significantly affect the company's business or stock performance.
The announcement is a clarification regarding regulatory filing requirements and does not contain any financial performance data or strategic updates that would positively or negatively impact the company's outlook.
Bal Pharma Limited has clarified that the statement of deviation or variation in the utilization of funds, as per Regulation 32(1) of SEBI (LODR) Regulations, 2015, is not applicable to the company for the quarter ended March 31, 2026.
This is because the company has not raised any funds through public issue, rights issue, preferential issue, or Qualified Institutional Placement (QIP) during the said period. Furthermore, there are no outstanding proceeds from earlier issues that require utilization.
The company has requested that this clarification be taken on record.
What to do with a filing like this
Bal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bal Pharma Limited. Read the original for the full detail.